tiprankstipranks
Trending News
More News >
Nanomix Corporation (NNMX)
OTHER OTC:NNMX
US Market
Advertisement

Nanomix (NNMX) Price & Analysis

Compare
20 Followers

NNMX Stock Chart & Stats


Financials

NNMX FAQ

What was Nanomix Corporation’s price range in the past 12 months?
Nanomix Corporation lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
    What is Nanomix Corporation’s market cap?
    Nanomix Corporation’s market cap is $49.00.
      When is Nanomix Corporation’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Nanomix Corporation’s earnings last quarter?
      Currently, no data Available
      Is Nanomix Corporation overvalued?
      According to Wall Street analysts Nanomix Corporation’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Nanomix Corporation pay dividends?
        Nanomix Corporation does not currently pay dividends.
        What is Nanomix Corporation’s EPS estimate?
        Nanomix Corporation’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Nanomix Corporation have?
        Nanomix Corporation has 48,996,760 shares outstanding.
          What happened to Nanomix Corporation’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Nanomix Corporation?
          Currently, no hedge funds are holding shares in NNMX

          Company Description

          Nanomix Corporation

          Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent necrosis, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It is also developing BTI-410, a peptide injectable compound, which is in Phase II clinical trial to stimulate beta cell maturation for development as a new insulin producing cell agent for the pancreas in type 2 diabetes patients and type 1 patients who are on immunosuppression therapy after having undergone kidney transplant surgery; SUGARDOWN, a non-systemic polysaccharide based dietary supplement to support healthy blood glucose levels; and OXYFEX, a veterinary medicine application used as an oxygen delivery agent similar to a RBC replacement for ischemia and trauma, as well as for blood loss during surgery. In addition, the company provides automatic retinal image analysis (ARIA), a diagnostic device for screening of cardiovascular risk, such as stroke. Boston Therapeutics, Inc. is headquartered in Lawrence, Massachusetts.
          Similar Stocks
          Company
          Price & Change
          Follow
          Orasure Technologies
          QuidelOrtho
          Trinity Biotech
          Accelerate Diagnostics
          Fulgent Genetics
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis